Replies to post #80427 on Amarantus Bioscience Holdings Inc (AMBS)

[gulf shores man]

About BD http://www.bd.com/us/about/

[zoomboom]

BD does it all. But its really a waste of time talking of that now.

Bascom Palmer was involved with this Orphan IND data. That is huge for AMBS abd MANF

Probably the most respected name in eye care in the world

[Solantey]

Becton Dickinson is expected to spend $500,000,000 in 2013 for R&D.

Company: Becton, Dickinson & Co.
Headquarters: Franklin Lakes, NJ
R&D spending fiscal 2011: $476 million
Priorities and Projects: The company ($BDX) known for its medical surgical systems, diabetes care products and diagnostic systems upped its R&D spending to $476 million in fiscal 2011, or 6.1% of revenues, versus $431 million and $405 million respectively in the previous two fiscal years. Take away $9 million from the 2011 spending--for a charge related to the discontinuation of a diagnostics system research program--and it is still a healthy increase year-over-year. According to a regulatory filing, spending at the company's R&D headquarters in Research Triangle Park, NC, and elsewhere targeted ongoing development of new products and platforms, including its BD Max and BD Viper molecular diagnostics systems.

Those new technologies enabled a push to expand molecular diagnostic test offerings. Becton, Dickinson's BD Diagnostics unit teamed up with the U.K.'s Lab21 in 2011, for example, to begin developing a diagnostics test for the Aspergillus fungus using the BD Max system. In late November, the company obtained a CE mark for its MRSA assay, also designed for the BD Max and a significant advance in diagnosing methicillin-resistant Staphylococcus aureus in patients. Becton Dickinson's development focus also expanded through acquisitions. In 2009, Becton Dickinson snatched up Accuri Cytometers for an undisclosed amount, gaining access to a well-known developer and maker of personal flow cytometers for researchers.